Le Fibroblast Growth Factor Receptor 3 (FGFR3), cible thérapeutique pour le traitement personnalisé du cancer de la vessie : validation anatomo-pathologique du concept
Prog Urol. 2014 Nov;24(13):806-7.
doi: 10.1016/j.purol.2014.08.054.
Epub 2014 Oct 30.
1 Service d'urologie, hôpital Foch, université de Versailles-Saint-Quentin-en-Yvelines, Suresnes, France. Electronic address: y.neuzillet@Hopital-foch.org.
2 Urology and Pathology, Netherlands Cancer Institute, Antoni van Leeuwenhoek Hospital, Amsterdam, Pays-Bas.
3 Urology and Pathology, University of Texas, Southwestern Medical center, Dallas, États-unis.
4 Urology, Pathology and Molecular medicine, University Health Network, Princess Margaret Hospital and Mount Sinai Hospital, University of Toronto, Toronto, Canada.
5 Urology and Pathology, University of Turku, Turku, Finlande.
6 Leeds Institute of Molecular Medicine, St James's University Hospital, Leeds, Royaume-Uni.